0936 ET - The new partnership between Hims & Hers Health and Novo Nordisk reflects the dependence each company has on the other, say Truist analysts. "The rapid cycle of litigation followed by reconciliation underscores that, while both parties lack trust, they remain bound by mutual necessity," the analysts say. Novo will benefit from Hims' direct-to-consumer channel, helping it to counter Eli Lilly's growing GLP-1 share, while Hims needed to offer legitimate, branded GLP-1s to offset declining GLP-1 compounding revenue. The partnership is only likely to hold "as long as commercial incentives remain aligned," the analysts say. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

March 09, 2026 09:37 ET (13:37 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.